These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8678035)

  • 21. Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma.
    Hsia CC; Nakashima Y; Thorgeirsson SS; Harris CC; Minemura M; Momosaki S; Wang NJ; Tabor E
    Oncol Rep; 2000; 7(2):353-6. PubMed ID: 10671685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deletion of chromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 and p15/MTS2 gene protein in hepatocellular carcinomas.
    Shao J; Li Y; Li H; Wu Q; Hou J; Liew C
    Chin Med J (Engl); 2000 Sep; 113(9):817-22. PubMed ID: 11776078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases.
    Raimondo G; Costantino L; Caccamo G; Pollicino T; Squadrito G; Cacciola I; Brancatelli S
    J Hepatol; 2004 Mar; 40(3):515-9. PubMed ID: 15123368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line.
    Chan KT; Lung ML
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):519-26. PubMed ID: 15004724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Australia antigen: a genetic basis for chronic liver disease and hepatoma?
    Sutnick AI; London WT; Blumberg BS
    Ann Intern Med; 1971 Mar; 74(3):443-4. PubMed ID: 4324024
    [No Abstract]   [Full Text] [Related]  

  • 26. TP53 and hepatocellular carcinoma.
    Puisieux A; Ozturk M
    Pathol Biol (Paris); 1997 Dec; 45(10):864-70. PubMed ID: 9769950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Numerical aberrations of chromosome 17 and the p53 locus in small hepatocellular carcinomas.
    Yano H; Nanashima A; Hidaka S; Haseba M; Tanaka K; Yamaguchi H; Nakagoe T; Tagawa Y; Nagayasu T
    Anticancer Res; 2004; 24(1):111-5. PubMed ID: 15015584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P53 codon 249 mutation in hepatocellular carcinomas from Nigeria.
    Ndububa DA; Yakicier CM; Ojo OS; Adeodu OO; Rotimi O; Ogunbiyi O; Ozturk M
    Afr J Med Med Sci; 2001; 30(1-2):125-7. PubMed ID: 14510167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Sequence alterations in p53 gene of hepatocellular carcinoma from high aflatoxin risk area in Guangxi].
    Deng Z; Pan L; Ma Y
    Zhonghua Zhong Liu Za Zhi; 1997 Jan; 19(1):18-21. PubMed ID: 10743047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GEP associates with wild-type p53 in hepatocellular carcinoma.
    Cheung ST; Wong SY; Lee YT; Fan ST
    Oncol Rep; 2006 Jun; 15(6):1507-11. PubMed ID: 16685387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis].
    Xue KX
    Ai Zheng; 2005 Jun; 24(6):757-68. PubMed ID: 15946497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
    Kubicka S; Trautwein C; Niehof M; Manns M
    Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 249ser p53 mutation in the serum of black southern African patients with hepatocellular carcinoma.
    Kimbi GC; Kew MC; Yu MC; Arakawa K; Hodkinson J
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1185-90. PubMed ID: 16048565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma.
    Moriyama Y; Nishiguchi S; Tamori A; Koh N; Yano Y; Kubo S; Hirohashi K; Otani S
    Clin Cancer Res; 2001 May; 7(5):1293-8. PubMed ID: 11350897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Gene TP53 and digestive cancers].
    Tominaga O; Salmon RJ; Laurent-Puig P
    Gastroenterol Clin Biol; 1993; 17(3):187-96. PubMed ID: 8392475
    [No Abstract]   [Full Text] [Related]  

  • 36. Prognosis in patients with hepatocellular carcinoma correlates to mutations of p53 and/or hMSH2 genes.
    Yano M; Hamatani K; Eguchi H; Hirai Y; MacPhee DG; Sugino K; Dohi K; Itamoto T; Asahara T
    Eur J Cancer; 2007 Apr; 43(6):1092-100. PubMed ID: 17350822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor.
    Cheung ST; Chen X; Guan XY; Wong SY; Tai LS; Ng IO; So S; Fan ST
    Cancer Res; 2002 Aug; 62(16):4711-21. PubMed ID: 12183430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Iron and chronic liver disease (excluding genetic hemochromatosis and metabolic liver siderosis)].
    Hezode C; Dhumeaux D
    Gastroenterol Clin Biol; 2000 May; 24(5 Pt 2):B82-7. PubMed ID: 10891769
    [No Abstract]   [Full Text] [Related]  

  • 39. [Characteristics of high frequency 249 codon mutation of p53 gene in hepatocellular carcinoma in prevalent area of China].
    Ming L; Yuan B; Thorgeirsson SS
    Zhonghua Zhong Liu Za Zhi; 1999 Mar; 21(2):122-4. PubMed ID: 11776852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression.
    Farazi PA; Glickman J; Horner J; Depinho RA
    Cancer Res; 2006 May; 66(9):4766-73. PubMed ID: 16651430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.